Adaptimmune Therapeutics Plc (ADAP)

$1.08

-0.06

(-5.26%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Adaptimmune Therapeutics Plc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 7.31M → 233.00K (in $), with an average decrease of 96.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 1.03M → -48.33M (in $), with an average decrease of 761.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 66.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 326.4%

Performance

  • $1.07
    $1.15
    $1.08
    downward going graph

    0.93%

    Downside

    Day's Volatility :6.96%

    Upside

    6.09%

    downward going graph
  • $0.42
    $2.05
    $1.08
    downward going graph

    61.11%

    Downside

    52 Weeks Volatility :79.51%

    Upside

    47.32%

    downward going graph

Returns

PeriodAdaptimmune Therapeutics PlcSector (Health Care)Index (Russel 2000)
3 Months
54.68%
2.0%
0.0%
6 Months
91.69%
11.7%
0.0%
1 Year
-13.64%
5.8%
1.3%
3 Years
-79.75%
14.2%
-22.1%

Highlights

Market Capitalization
258.1M
Book Value
$0.17
Earnings Per Share (EPS)
-0.54
PEG Ratio
0.11
Wall Street Target Price
3.5
Profit Margin
-188.9%
Operating Margin TTM
-21582.68%
Return On Assets TTM
-28.22%
Return On Equity TTM
-187.61%
Revenue TTM
60.3M
Revenue Per Share TTM
0.3
Quarterly Revenue Growth YOY
-97.89999999999999%
Gross Profit TTM
-100.6M
EBITDA
-128.2M
Diluted Eps TTM
-0.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.28
EPS Estimate Next Year
-0.42
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    64%Buy
    28%Hold
    7%Sell
Based on 14 Wall street analysts offering stock ratings for Adaptimmune Therapeutics Plc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
4
4
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 224.07%

Current $1.08
Target $3.50

Company Financials

FY18Y/Y Change
Revenue
59.5M
↑ 57.28%
Net Income
-95.5M
↑ 36.18%
Net Profit Margin
-160.51%
↑ 24.88%
FY19Y/Y Change
Revenue
1.1M
↓ 98.11%
Net Income
-137.2M
↑ 43.61%
Net Profit Margin
-12.2K%
↓ 12064.53%
FY20Y/Y Change
Revenue
4.0M
↑ 252.76%
Net Income
-130.1M
↓ 5.16%
Net Profit Margin
-3.3K%
↑ 8938.23%
FY21Y/Y Change
Revenue
6.1M
↑ 55.36%
Net Income
-158.1M
↑ 21.52%
Net Profit Margin
-2.6K%
↑ 715.82%
FY22Y/Y Change
Revenue
27.1M
↑ 341.5%
Net Income
-165.5M
↑ 4.66%
Net Profit Margin
-609.46%
↑ 1961.53%
FY23Y/Y Change
Revenue
60.5M
↑ 122.91%
Net Income
-114.3M
↓ 30.91%
Net Profit Margin
-188.9%
↑ 420.56%
Q3 FY22Q/Q Change
Revenue
7.0M
↑ 26.53%
Net Income
-41.4M
↓ 6.96%
Net Profit Margin
-591.14%
↑ 212.76%
Q4 FY22Q/Q Change
Revenue
11.0M
↑ 57.39%
Net Income
-29.3M
↓ 29.38%
Net Profit Margin
-265.23%
↑ 325.91%
Q1 FY23Q/Q Change
Revenue
47.6M
↑ 331.64%
Net Income
1.0M
↓ 103.54%
Net Profit Margin
2.18%
↑ 267.41%
Q2 FY23Q/Q Change
Revenue
5.1M
↓ 89.22%
Net Income
-21.4M
↓ 2164.58%
Net Profit Margin
-416.94%
↓ 419.12%
Q3 FY23Q/Q Change
Revenue
7.3M
↑ 42.67%
Net Income
-45.6M
↑ 113.2%
Net Profit Margin
-623.05%
↓ 206.11%
Q4 FY23Q/Q Change
Revenue
233.0K
↓ 96.82%
Net Income
-48.3M
↑ 5.99%
Net Profit Margin
-20.7K%
↓ 20120.28%
FY18Y/Y Change
Total Assets
276.7M
↓ 1.57%
Total Liabilities
29.9M
↓ 61.81%
FY19Y/Y Change
Total Assets
181.5M
↓ 34.4%
Total Liabilities
57.9M
↑ 93.98%
FY20Y/Y Change
Total Assets
451.1M
↑ 148.5%
Total Liabilities
109.9M
↑ 89.82%
FY21Y/Y Change
Total Assets
469.5M
↑ 4.08%
Total Liabilities
263.6M
↑ 139.81%
FY22Y/Y Change
Total Assets
328.9M
↓ 29.95%
Total Liabilities
247.0M
↓ 6.28%
FY23Y/Y Change
Total Assets
282.6M
↓ 14.08%
Total Liabilities
243.1M
↓ 1.59%
Q3 FY22Q/Q Change
Total Assets
332.2M
↓ 14.44%
Total Liabilities
218.9M
↓ 11.16%
Q4 FY22Q/Q Change
Total Assets
328.9M
↓ 0.99%
Total Liabilities
247.0M
↑ 12.87%
Q1 FY23Q/Q Change
Total Assets
288.1M
↓ 12.42%
Total Liabilities
204.2M
↓ 17.34%
Q2 FY23Q/Q Change
Total Assets
343.0M
↑ 19.06%
Total Liabilities
216.3M
↑ 5.94%
Q3 FY23Q/Q Change
Total Assets
296.6M
↓ 13.51%
Total Liabilities
208.5M
↓ 3.62%
Q4 FY23Q/Q Change
Total Assets
282.6M
↓ 4.73%
Total Liabilities
243.1M
↑ 16.59%
FY18Y/Y Change
Operating Cash Flow
-104.4M
↑ 92.19%
Investing Cash Flow
-17.5M
↓ 86.15%
Financing Cash Flow
102.7M
↓ 0.85%
FY19Y/Y Change
Operating Cash Flow
-112.5M
↑ 7.78%
Investing Cash Flow
94.9M
↓ 643.88%
Financing Cash Flow
366.0K
↓ 99.64%
FY20Y/Y Change
Operating Cash Flow
-53.6M
↓ 52.37%
Investing Cash Flow
-278.9M
↓ 393.77%
Financing Cash Flow
340.1M
↑ 92810.11%
FY21Y/Y Change
Operating Cash Flow
10.7M
↓ 120.02%
Investing Cash Flow
75.8M
↓ 127.18%
Financing Cash Flow
3.3M
↓ 99.03%
FY22Y/Y Change
Operating Cash Flow
-141.8M
↓ 1421.36%
Investing Cash Flow
89.1M
↑ 17.59%
Financing Cash Flow
12.9M
↑ 291.33%
Q3 FY22Q/Q Change
Operating Cash Flow
-48.2M
↑ 16.75%
Investing Cash Flow
28.9M
↓ 34.59%
Financing Cash Flow
1.5M
↓ 85.45%
Q4 FY22Q/Q Change
Operating Cash Flow
2.0M
↓ 104.24%
Investing Cash Flow
21.0M
↓ 27.38%
Financing Cash Flow
1.4M
↓ 3.37%
Q1 FY23Q/Q Change
Operating Cash Flow
-37.3M
↓ 1925.81%
Investing Cash Flow
2.7M
↓ 87.14%
Financing Cash Flow
196.0K
↓ 86.03%
Q2 FY23Q/Q Change
Operating Cash Flow
-43.8M
↑ 17.38%
Investing Cash Flow
2.7M
↑ 0.0%
Financing Cash Flow
14.0K
↓ 92.86%
Q3 FY23Q/Q Change
Operating Cash Flow
-45.2M
↑ 3.19%
Investing Cash Flow
57.3M
↑ 2027.17%
Financing Cash Flow
596.0K
↑ 4157.14%

Technicals Summary

Sell

Neutral

Buy

Adaptimmune Therapeutics Plc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc
-20.83%
91.69%
-13.64%
-79.75%
-75.54%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
11.53%
21.99%
86.62%
131.89%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc
NA
NA
0.11
-0.28
-1.88
-0.28
NA
0.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc
Buy
$258.1M
-75.54%
NA
-188.9%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
131.89%
28.81
36.68%

Institutional Holdings

  • Matrix Capital Management Company, LLC

    15.79%

  • NEA Management Company, LLC

    6.92%

  • Baillie Gifford & Co Limited.

    6.45%

  • Long Focus Capital Management, LLC

    4.90%

  • Baker Bros Advisors LP

    4.44%

  • Partner Fund Management LP

    4.22%

Corporate Announcements

  • Adaptimmune Therapeutics Plc Earnings

    Adaptimmune Therapeutics Plc’s price-to-earnings ratio stands at None

    Read More

Company Information

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Organization
Adaptimmune Therapeutics Plc
Employees
449
CEO
Mr. Adrian G. Rawcliffe
Industry
Health Technology

Discover More

FAQs